AMD

Early clinical experience highlights considerations for patient selection, surgical technique, and long-term monitoring in retinal disease.

The superiority primary endpoint at week 36 was met with high statistical significance, and AXPAXLI showed either statistical significance or numerical superiority to aflibercept (2 mg) in key secondary and prespecified exploratory endpoints.

Under the US agreement, OPUVIZ (aflibercept-yszy), a biosimilar to Eylea (aflibercept) 2 mg, may launch in January 2027.

A closer look at the science powering next-generation retinal treatments

Reduced tobacco use and access to care are key components

Aaron Y. Lee, MD, MSCI, explains how temporal optical coherence tomography modeling may improve longitudinal disease tracking and clinical decision-making at Angiogenesis 2026.

The primary endpoint of the trial is non-inferiority in the mean change from baseline in best-corrected visual acuity (BCVA) at 52 weeks.

The results of a multicenter controlled clinical trial showed that the device resulted in “a significant improvement in visual acuity (VA) from baseline to month 12.

Metformin, a common diabetes medication, may be associated with less development of intermediate age-related macular degeneration (AMD).

MTII tracking in geographic atrophy reveals central macula preservation and predicts vision loss better than lesion area, shaping future trial endpoints.

Key clinical trial data and PDUFA dates in early 2026 focus on treatments for dry eye, AMD, and rare eye diseases.

The Investigational New Drug (IND) application from Complement Therapeutics for CTx001 was previously approved by the FDA in October 2025.

A trio of retina specialists recently reviewed the clinical benefits of aflibercept 8 mg, including its extended dosing intervals, improved patient satisfaction, and enhanced treatment outcomes for various conditions.

Knowing what’s on the market for AMD and GA aids in preserving vision.

The JADE clinical study enrolled more than 160 patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD).

The novel system converts light into electrical signals to stimulate retinal cells.

The FDA noted in the letter that it is unable to approve the application for ONS-5010/LYTENAVA (bevacizumab-vikg) in its current form for the treatment of wet AMD.

The letter noted the FDA is unable to approve the application for ONS-5010/LYTENAVA (bevacizumab-vikg) in its current form for the treatment of wet AMD, according to the company.

Strategies for treatment intervals, drug selection, and patient expectations.

A trio of retina specialists recently reviewed the clinical benefits of aflibercept 8 mg, including its extended dosing intervals, improved patient satisfaction, and enhanced treatment outcomes for various conditions.

This approach helps distinguish diseases associated with macular atrophy.

Remote monitoring of age-related macular degeneration enhances patient care, reduces treatment burden, and leverages AI for personalized management.